News

Video

5-Year Follow-up of the Phase 2 Optic Study in Patients with Chronic-Phase Chronic Myeloid Leukemia: Efficacy, Safety, and First End-of-Treatment Mutational Results

Dr. Jorge E. Cortes provides a comprehensive overview of the 5-year follow-up results from the Phase 2 OPTIC study, showcasing the long-term efficacy, safety, and mutational analysis of ponatinib in patients with chronic-phase chronic myeloid leukemia, including outcomes related to dose modifications and mutation evolution.

Related Videos
CDAC CLL
Epcore DLBCL-3 First Disclosure: Fixed-Duration Epcoritamab Monotherapy in Older (≥75 y), Anthracycline-Ineligible Patients with Previously Untreated Large B-Cell Lymphoma
Isatuximab, Lenalidomide, Bortezomib and Dexamethasone Induction Therapy for Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma: Final Progression-Free Survival Analysis of Part 1 of an Open-label, Multicenter, Randomized, Phase 3 Trial (GMMG-HD7)
Phase 3 AMPLIFY Trial
BOVen
RMC-6236
LTE-1 ASPEN LTFU
Data from an Ongoing Phase 1/1b Study BGB-11417-101
Preliminary Results from the IMMagine-1 Trial
Related Content